Community Gonadorelin Analogue Service

Tender description

The Castle Point and Rochford Clinical Commissioning Group wishes to secure Providers for the provision of Gonadorelin Analogues services for the treatment of carcinoma of the prostate. There are a number of treatment regimes, which vary in the detail of their programme of administration and main purpose. Broadly they can be divided on the basis of the progress of the disease into advanced local disease and metastatic disease. The central usage, however, remains the treatment of metastatic cancer of the prostate. Currently it is estimated that over 95% of the scripts for Gonadorelin analogues are written for Ca Prostate. Gonadorelins are used primarily in the treatment of carcinoma of the prostate. There are a number of treatment regimes, which vary in the detail of their programme of administration and main purpose. Broadly they can be divided on the basis of the progress of the disease into advanced local disease and metastatic disease. The central usage, however, remains the treatment of metastatic cancer of the prostate. Currently it is estimated that over 95% of the scripts for Gonadorelin analogues are written for Ca Prostate. It is recognised that gonadorelins are also sometimes used in the treatment of breast cancer and endometriosis and these treatments are also covered under this agreement. The Provider must: • Provide a register - Providers will need to produce and maintain a valid up-to-date register of patients being treated as part of this service. • Demonstrate a call and recall system - Providers will need to ensure a systematic call and recall of patients on this register is taking place, and have in place the means to identify and follow up patients in default.